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Introduction 
A full understanding of nerve regeneration, namely complete 
functional achievement and organ re-innervation after nerve 
injury, still remains a main goal for regenerative medicine. 
Peripheral nerve injury has a high regenerative potential, but 
functional recovery rarely occurs after total nerve 
transection. In the peripheral nervous system, nerves can 
spontaneously regenerate without any treatment if nerve 
continuity is maintained (axonotmesis), whereas more 
severe type of injuries must be surgically treated by direct 
end-to-end surgical reconnection of the damaged nerve ends 
[1-3]
.  Cell transplantation has been proposed as a method for 
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Peripheral nerves have the intrinsic capacity of self-regeneration after traumatic injury but the extent of the regeneration is often 
very poor. Increasing evidence demonstrates that mesenchymal stem/stromal cells (MSCs) may play an important role in tissue 
regeneration through the secretion of soluble trophic factors that enhance and assist in repair by paracrine activation of 
surrounding cells. In the present study, the therapeutic value of a population of umbilical cord tissue-derived MSCs, obtained by a 
proprietary method (UCX
®
), was evaluated on end-to-end rat sciatic nerve repair. Furthermore, in order to promote both, end-to-
end nerve fiber contacts and MSC cell-cell interaction, as well as reduce the flush away effect of the cells after administration, a 
commercially available haemostatic sealant, Floseal
®
, was used as vehicle. Both, functional and morphologic recoveries were 
evaluated along the healing period using extensor postural thrust (EPT), withdrawal reflex latency (WRL), ankle kinematics 
analysis, and either histological analysis or stereology, in the hyper-acute, acute and chronic phases of healing. The histological 
analysis of the hyper-acute and acute phase studies revealed that in the group treated with UCX
®
 alone the Wallerian 
degeneration was improved for the subsequent process of regeneration, the fiber organization was higher, and the extent of 
fibrosis was lower. The chronic phase experimental groups revealed that treatment with UCX
®
 induced an increased number of 
regenerated fibers and thickening of the myelin sheet. Kinematics analysis showed that the ankle joint angle determined for 
untreated animals was significantly different from any of the treated groups at the instant of initial contact (IC). At opposite toe off 
(OT) and heel rise (HR), differences were found between untreated animals and the groups treated with either UCX
®
 alone or 
UCX
®
 administered with Floseal
®
. Overall, the UCX
®
 application presented positive effects in functional and morphologic recovery, 
in both the acute and chronic phases of the regeneration process. Kinematics analysis has revealed positive synergistic effects 
brought by Floseal
®
 as vehicle for MSCs.  
 
improving peripheral nerve regeneration 
[4]
, including Schwann 
cell (SC) transplantation that can enhance axon outgrowth and 
survival, both in vitro 
[5]
 and in vivo 
[6]
. Mesenchymal stem cells 
(MSCs) have become one of the most interesting agents for 
regenerative medicine. Scientific and clinical evidence have 
demonstrated that MSCs have the ability to migrate to specific 
sites of injury or of tissue regeneration where they modulate the 
immune and the inflammatory responses and mobilize intrinsic 
cell reservoirs through a series of distinct paracrine mechanisms 
[7]
.  Furthermore, MSCs are not only capable of differentiating 
into   tri-lineage   mesenchyme  cell  types,  such  as  adipocytes, 
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chondrocytes and osteoblasts 
[8]
, but also into neuronal-like 
cells, including astrocytes, oligodendrocytes, microglial, 
neurons and neuroglial cells 
[9-11]
. MSCs have been isolated 
from various types of adult tissues, the bone marrow being 
the most commonly used (BM-MSCs). Dezawa and 
collaborators in 2001 showed that autologous BM-MSCs 
were capable of differentiating into cells with Schwann cell 
properties 
[12, 13]
.  BM-MSCs have been applied for cell-based 
therapies. However, factors such as the limited number of 
BM-MSCs available, the heterologous and non-consistent 
nature of bone marrow preparations, the possibility of donor 
site morbidity, and the decreasing number of BM-MSCs with 
donor age, make it imperative that alternative and more 
primordial MSCs sources are found. Different isolation 
procedures have led to umbilical cord tissue-derived MSCs 
(UC-MSCs) that exhibit a neuronal phenotype 
[14-17]
 and have 
potential utility for the treatment of neurodegenerative 
diseases 
[18, 19]
. Interestingly, these cells, which are major 
histocompatibility complex (MHC) class II negative, are able 
to both evade and modulate the immune system 
[16]
, making 
them an attractive cell source for MSC-based therapies. In 
addition, these cells represent a non-controversial source of 
primitive mesenchymal progenitor cells that can be isolated 
after birth, cryogenically stored, thawed, and expanded for 
therapeutic uses 
[20]
. Within our group, a method to 
consistently isolate, expand, and cryopreserve a well-
characterized population of human stem cells derived from 
the umbilical cord tissue has been developed and such cells 
termed as UCX
® [21]
.  The isolation method has been 
specifically designed for clinical use and it has been recently 
adapted according to advanced therapy medicinal product 
(ATMP) standards, as defined by the guideline on the 
minimum quality data for certification of ATMP 
(EMA/CAT/486831/2008/corr, 2010) (results to be published 
elsewhere). More recently, the UCX
®
 paracrine activity has 
been demonstrated to repress T-cell activation better than 
BM-MSCs and to promote the expansion of Tregs. 
Accordingly, the xenogenic UCX
® 
administration in an acute
 
inflammation model showed that UCX
® 
can reduce paw 
edema in vivo more efficiently than BM-MSCs 
[22]
. Finally, 
animals treated with intra-articular (i.a.) and intra-peritoneal 
(i.p.) infusions of UCX
®
 showed faster and almost full 
remission of local and systemic arthritis manifestations, 
potentially demonstrating a potent paracrine induction of 
tissue regeneration 
[22]
. 
 
Biomaterials are known to be able to support cellular systems 
to either differentiate into neuroglial-like cells or to enhance 
their paracrine effects on the overall regenerative process. 
Concomitantly, biomaterials can be directly involved in the 
regenerative process, helping to improve the motor and 
sensory functional recovery, shortening the healing period 
and avoiding regional muscular atrophy 
[1, 20, 23]
.  Floseal
®
 is a 
commercially available haemostatic sealant composed of 
collagen-derived particles and topical bovine-derived 
thrombin, which has been proven to control bleeding in 
several medical applications 
[24, 25]
.  Floseal
®
 has been 
previously applied in vivo in bone regeneration, associated to 
the synthetic graft Bonelike
®
 and raloxifene hydrochloride, 
increasing osteointegration of Bonelike
®
 granules and new 
bone formation 
[26]
. In this study, we hypothesized that UCX
®
 
could  be integrated surrounding the sectioned sciatic nerve 
(neurotmesis) and modulate the inflammatory response, 
including the Wallerian degeneration that occurs in the hyper- 
 
 
 
 
 
 
 
 
 
 
acute phase after injury 
[27]
. We also hypothesized that 
Floseal
® 
used as vehicle could help promoting end-to-end 
contact between nerve fibers and MSC cell-cell interactions 
within the suture, as well as maintaining UCX
®
 cells within 
the wounded site. In order to test this hypothesis, the 
therapeutic value of UCX
®
 was evaluated on end-to-end rat 
sciatic nerve repair after neurotmesis in the hyper-acute and 
acute healing phases since the Wallerian degeneration 
occurring during the first days after the injury is crucial for an 
effective regeneration. On the other hand, a functional and 
morphometric analysis in the chronic phase allowed for the 
evaluation of the actual nerve regeneration. Overall, our 
results suggest that the application of UCX
®
 and Floseal
® 
presented synergistic positive effects in functional and 
morphological recoveries in the overall nerve regeneration 
process.  
 
Materials and methods 
 
2.1 Ethics and regulation 
 
Umbilical cord donations were obtained with written informed 
consents according to Directive 2004/23/EC, which sets the 
standards of quality and safety for the donation, 
procurement, testing, processing, preservation, storage and 
distribution of human tissues and cells. All the animal testing 
procedures were in conformity with the Directive 2010/63/EU 
of the European Parliament and with the approval of the 
Veterinary Authorities of Portugal in accordance with the 
European Communities Council Directive of November 1986 
(86/609/EEC). Humane end points were followed in 
accordance to the OECD Guidance Document on the 
Recognition, Assessment and Use of Clinical Signs as 
Humane Endpoints for Experimental Animals Used in Safety 
Evaluation (2000). Adequate measures were taken to 
minimize pain and discomfort taking into account human 
endpoints for animal suffering and distress. Animals were 
housed for two weeks before entering the experiment. 
 
2.2. UCX
®
 Isolation and Culture 
 
Cells were isolated from the umbilical cord tissue as in 
Santos et al. 2008 (INPI 103843, PCT/IB2008/054067, 
WO/2009/044379) with a number of minor alterations. Briefly, 
after 24h in contact with a saline solution containing 
antibiotics and anti-mycotics, umbilical cords were cleared of 
blood clots and transversely sectioned in 2.5 cm portions.  
These pieces were subsequently treated with a digestion 
solution containing collagenase and trypsin, for 4h at 37ºC 
after which cells were allowed to adhere to the lower surface 
of a t-flask for 30 min. After this time, the liquid media was 
collected and centrifuged at 200g at 4ºC for 5 min, 
supernatant was collected and returned to the original t-flask 
and the pellet was discarded.  The isolated cells were 
maintained in a humidified chamber at 37ºC and 7% CO2, 
cells were subject to regular medium replacements and 
maintained until 80% of confluency.  The MSCs phenotype 
was confirmed by flow cytometry. Detection was performed 
with the following antibodies and their respective isotypes (all 
from BioLegend unless stated otherwise): PE anti-human 
CD105 (eBioScience); APC anti-human CD73; PE anti-
human CD90; PerCP/Cy5.5 anti-human CD45: FITC anti-
human CD34;; PerCP/Cy5.5 anti-human CD14; Pacific Blue 
anti-human CD19 and pacific-blue anti-human HLA-DR. 
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UCX
®
 were maintained in culture in α-MEM (Minimum Essential 
Medium Eagle’s Alpha Modification, Sigma - Aldrich) with 2mM 
glutamine, supplemented with 20% FBS (heat inactivated Fetal 
Bovine Serum, Invitrogen™) at 37ºC in a 5% CO2, humid 
environment. For cell passage, PBS (Dulbecco’s Phosphate 
Buffered Saline, Sigma-Aldrich) was used prior to trypsinization 
to wash cells, followed by contact with TrypLE™ Select 
(Invitrogen™). TrypLE™ Select was inactivated by addition of 
PBS and subsequent centrifugation at 200g for 10 min 
(Sartorius, Model: 2-6). Seeding density was 1x10
4
cells/cm
2
, 
unless indicated otherwise. Cell viability was evaluated using 
the trypan blue (Sigma-Aldrich) exclusion method (Figures 1A 
and 1B).  
 
2.3. UCX
®
 Tri-Lineage Differentiation 
 
To induce adipogenic differentiation, UCX
®
 were cultured for 3 
days in adipogenic differentiation medium, consisting of α-MEM 
supplemented with 20% FBS, 2 mM L-glutamine, 10 µg/mL 
insulin (Sigma-Aldrich), 200 µM indomethacin (Sigma-Aldrich), 
0.5 mM isobutylmetylxantine (Sigma-Aldrich), and 1 µM 
dexamethasone (Sigma-Aldrich); and subsequently 1 day in 
adipogenic maintenance medium, consisting of α-MEM 
supplemented with 20% FBS, 2 mM L-glutamine and 10 µg/mL 
insulin. Medium was replaced every 3 days during 21 days, 
after which histochemical staining was performed. For 
chondrogenic differentiation, cells were grown in suspension as 
pellets, incubated in chondrogenic differentiation medium 
consisting on DMEM-LG (Sigma-Aldrich), 1% FBS, 2 mM L-  
glutamine, 6.25 µg/mL insulin (Sigma-Aldrich), 10 ng/mL 
TGF-β1 (Tebu-bio), and 50 µM ascorbate-2-phosphate 
(Sigma-Aldrich). Finally, to induce osteogenic differentiation, 
cells were incubated in osteogenic differentiation medium 
whose composition is α-MEM, 10% FBS, 1 g/L glucose, 2 
mM glutamine, 10 mM β-glycerol phosphate, 50 µg/mL 
ascorbate-2-phosphate, and 100 nM dexamethasone (all 
reagents are from Sigma-Aldrich). The medium was replaced 
every 3 days during 21 days and histochemical staining was 
performed. In adipogenic and osteogenic differentiation 
protocols, cells were washed and fixed with 
paraformaldehyde 4% for 20 min and stained with oil red O 
and alkaline phosphatase, respectively. For chondrogenic 
differentiation, cells were also fixed in paraformaldehyde 4%, 
dried, embedded in paraffin and cut into sections and finally 
stained with alcian blue. The presence of stained cells was 
confirmed by inverted microscopy with phase contrast (Leica, 
DMIL HC) (Figure 1C). 
 
2.4. Vehicle preparation and UCX
®
 association 
 
Floseal
®
 is a ready-to-use commercial hemostatic matrix, 
also applied in neurosurgery; the application kit consists of a 
bovine-derived gelatin matrix, a human derived thrombin 
component, applicator tips and several mixing accessories. 
Floseal
®
 is biocompatible and resorbed within 6 to 8 weeks.  
The preparation of the Floseal
®
 prior to use followed the 
manufacture instructions (www.floseal.com).  Briefly, using 
the   5 ml   syringe   with   needle-attached  provided  in   the  
Mesenchymal stem cells for nerve regeneration 
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Figure 1 - UCX
®
 characterization. Isolated UCX
®
 presented a fusiform, fibroblast-like morphology in culture (A). Results from Flow Cytometry analysis of cell 
surface markers are presented as histograms (B). Multi-lineage differentiation potential of UCX
®
 was qualitatively analyzed by histological staining methods 
(C). Adipogenic differentiation was assessed with Oil Red O staining (C, i); osteogenic differentiation with Alkaline Phosphatase staining (C, ii) and 
chondrogenic differentiation with Alcian Blue staining (C, iii). 
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thrombin component package, the 5 ml chloride solution is 
transferred to the vial containing the thrombin. The dissolved 
thrombin is aspirated from the small bowl into the syringe to 
the indicated mark (4 ml) and the gelatin matrix granules 
syringe is connected to the syringe containing the thrombin 
solution and the gelatin matrix – thrombin solution mixture is 
transferred back and forth between the syringes for a total of 
10 passes (Figure 2A). 
 
Intracellular free Ca
2+
 concentration ([Ca
2+
]i) was measured 
in Fura-2-loaded MSCs by using dual wavelength 
spectrofluorometry as previously described 
[1]
. The 
measurements were performed on UCX
® 
cells mixed with 
Floseal
®
 on discs in order to correlate MSC survival capacity 
with the presence of Floseal
®
. Results obtained from 
epifluorescence technique are referred to measurements 
from UCX
® 
cells which correspond to [Ca
2+
]i from cells that 
did not begin the apoptosis process (data not shown). 
According to these results, it is reasonable to conclude that 
Floseal
®
 is a viable substrate for local delivery of 
undifferentiated MSCs into the nerve injury. 
 
2.5. Microsurgical procedure 
 
Adult male Sasco Sprague Dawley rats (Charles River 
Laboratories, Barcelona, Spain) weighing 250-300 g, were 
randomly divided into groups of 6 to 7 animals each. For 
surgery, animals were placed prone under sterile conditions 
and the skin from the clipped lateral right thigh scrubbed in a 
routine fashion with antiseptic solution. The surgeries were 
performed under an M-650 operating microscope (Leica 
Microsystems, Wetzlar, Germany). Under deep anesthesia 
(ketamine 90 mg/Kg; xylazine 12.5 mg/Kg, atropine 0.25 
mg/Kg i.m.), the right sciatic nerve was exposed through a 
skin incision extending from the greater trochanter to the mid-
thigh distally followed by a muscle splitting incision. After 
nerve mobilization, a transection injury was performed 
(neurotmesis) immediately above the terminal nerve 
ramification using straight microsurgical scissors. For the 
acute phase study, animals were randomly assigned to 3 
experimental groups. In the first group (End-to-End), 
immediate cooptation with 7/0 monofilament nylon epineural 
sutures of the 2 transected nerve endings. In the second 
group (End-to-EndUCX group) the animals received the 
same treatment as the previous group, but the injury local 
was infiltrated with UCX
®
 suspended in culture medium. The 
third group was composed of 6 healthy animals without any 
injury (Control). For these groups, animals were euthanized  
21 days (week 3) after the neurotmesis injury and surgery 
procedure. Animals were then randomly assigned to five 
experimental groups, and included in the chronic phase 
study. In a first group (End-to-End), immediate cooptation 
with 7/0 monofilament nylon epineural sutures of the 2 
transected nerve endings was performed. In a second group 
(End-to-EndFlosealUCX group), nerve transaction was 
reconstructed by end-to-end suture, like in the first group, 
and then locally enwrapped with UCX
®
 mixed with Floseal
®
. 
In a third group (End-to-EndUCX group) animals received the 
same treatment as the previous group, but locally infiltrated 
with UCX
®
 alone, suspended in culture medium. In a fourth 
group (End-to-EndFloseal group), animals received the same 
treatment as the previous group, but locally enwrapped with 
Floseal
®
 alone. Also, a group of 6 animals without any injury 
was included (Control).   
 
 
 
 
 
 
 
 
For these groups, animals were euthanized 20 weeks after 
the neurotmesis injury and surgery procedure. In both 
studies, 5000 viable UCX
®
 cells were applied / neurotmesis 
lesion in a volume of 20 µl of culture medium. In order to also 
evaluate the effect of UCX
®
 in the hyper-acute phase of the 
healing period, 4 more animals were euthanized 3 days after 
the surgical procedure for repairing the neurotmesis lesion 
and submitted to histological analysis: end-to-end suture 
(End-to-End), end-to-end suture covered by Floseal
®
 (End-
to-EndFloseal), end-to-end suture infiltrated with UCX
®
 (End-
to-EndUCX), and end-to-end suture with UCX
®
 mixed with 
Floseal
® 
(End-to-EndFlosealUCX). In this experimental 
group, 5000 viable UCX
®
 cells were also applied in the 
neurotmesis lesion either suspended in 20 µl of culture 
medium or in the appropriate vehicle (Floseal
®
). UCX
®
 cells 
were either infiltrated into the interfascicular epineurium in 
the End-to-EndUCX groups or placed in contact to the 
external side of the nerve epineurium in the End-to-
EndFlosealUCX groups. These surgical procedures limited 
the systemic dissemination of the MSCs and improved the 
local application of these MSCs in the injury site. Since all the 
experimental animals are euthanized after the healing period 
of 3 days, 3 weeks and 20 weeks for the hyper-acute, acute 
and chronic study, respectively, the same animals were not 
used in the three different healing period studies. To prevent 
autotomy, a deterrent substance was applied to the animals’ 
right paw 
[28, 29]
. The animals were intensively examined for 
signs of autotomy and contracture post-operative and none 
presented severe infections (Figures 2B, 2C and 2D). 
 
2.6. Functional assessment  
 
The chronic phase groups (End-to-End; End-to-
EndFlosealUCX; End-to-EndUCX; End-to-EndFloseal, 
Control) were tested pre-operatively (week 0), at week 1 and 
then, every 2 weeks until the end of follow-up time (20 
weeks). The acute phase group (End-to-End, End-to-
EndUCX, and Control) were tested pre-operatively (week 0), 
and at days 7 (week 1), 14 (week 2) and 21 (week 3). 
Animals were gently handled, and tested in a quiet 
environment to minimize stress. No functional assessment 
was performed in the hyper-acute phase experimental group. 
 
Evaluation of motor performance (EPT) and nociceptive 
function (WRL) 
 
Motor performance and nociceptive function were evaluated 
by measuring extensor postural thrust (EPT) and withdrawal 
reflex latency (WRL), respectively. The animals were tested 
pre-operatively (week 0), at day 7 (week 1), 14 (week 2), and 
21 (week 3) (Acute phase study); and pre-operatively (week 
0) and were tested pre-operatively (week 0), at week 1 and 
afterwards, every 2 weeks until the end of follow-up time (20 
weeks) (Chronic phase study). The EPT was originally 
proposed by Thalhammer and collaborators, in 1995 
[30]
 as  
part of the neurological recovery evaluation in the rat after 
sciatic nerve injury. For this test, the entire body of the 
animal, with exception of the hind-limbs, is wrapped in a 
surgical towel.  EPT is induced by supporting the animal by 
the thorax and lowering the affected hind-limb towards the 
platform of a digital balance. As the animal is lowered to the 
platform, it extends the hind-limb, anticipating the contact 
made by the distal metatarsus and digits. 
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Figure 2 – Floseal
®
 preparation, rat sciatic nerve injury and surgical reconstruction. The 5 ml chloride solution is transferred to a vial containing thrombin. The 
vial is gently swirled until the thrombin is dissolved. The dissolved thrombin is aspirated from the small bowl into the syringe to the indicated mark (4 ml) and 
the gelatin matrix granules syringe is connected to the syringe containing the thrombin solution and the gelatin matrix – thrombin solution mixture is 
transferred back and forth between the syringes for a total 10 passages (A). Rat sciatic nerve reconstructed with an end-to-end suture and Floseal
®
 (End-to-
EndFloseal group) (B). Rat sciatic nerve with a neurotmesis injury with a gap of 10 mm (C). The neurotmesis injury was performed and regeneration initiated 
after reconstruction with an end-to-end suture where the coaptation was performed with 7/0 monofilament nylon epineural sutures of the 2 transected nerve 
endings (D). 
 
The force in grams (g) applied to the digital platform balance 
is recorded. The same procedure is applied to the contra-
lateral, unaffected limb. For the EPT test, the affected and 
normal limbs are tested 3 times, with an interval of 2 minutes 
between consecutive tests, and the 3 values are averaged to 
obtain a final result. The normal (unaffected limb) EPT 
(NEPT) and experimental EPT (EEPT) values are 
incorporated into an equation (Equation (1)) to derive the 
percentage of functional deficit, as described in the literature 
[23, 31-34]
.  
% Motor deficit = [(NEPT – EEPT) / NEPT] × 100 (1) 
 
To assess the nociceptive withdrawal reflex (WRL), the 
hotplate test was modified as described by Masters and 
collaborators 
[35]
. The animal is wrapped in a surgical towel 
above its waist and then positioned to stand with the affected 
hind paw placed on a hot plate, at 56ºC, and with the other 
on a room temperature plate. WRL is defined as the time 
elapsed from the onset of hotplate contact to withdrawal of 
the hind paw and measured with a stopwatch. Normal 
animals withdraw their paws from the hotplate within 4.3 s or 
less 
[1, 23, 34, 36]
. The affected limbs were tested 3 times, with 
an interval of 2 min between consecutive tests to prevent 
sensitization, and the three latencies were averaged to obtain 
a final result 
[37]
. If there was no paw withdrawal after 12 s, 
the heat stimulus was removed to prevent tissue damage, 
and the animal was assigned the maximal WRL of 12 s 
[38, 39]
. 
 
Kinematics analysis  
 
Ankle kinematics was carried out prior nerve injury (week 0), 
and at the 20-week follow-up time and it was only performed 
in the chronic phase study in the following experimental 
groups: End-to-End, End-to-EndFlosealUCX, End-to-
EndUCX, and End-to-EndFloseal group. 
 
 
 
 
 
Also, a group of 6 animals without any injury was included 
(Control). Animals walked on a Perspex track with length, 
width and height of 120, 12, and 15 cm, respectively. In order 
to ensure locomotion in a straight line, the width of the 
apparatus was adjusted to the actual animal size during the 
experiments. The animals’ gait was video recorded at a rate 
of 300 images per second (Casio Exilim PRO EX-F1, Japan). 
The camera was positioned at the track half-length where 
gait velocity was steady, and 1 m distant from the track 
obtaining a visualization field of 14 cm wide. The video 
images were stored in a computer hard disk for later analysis 
using an appropriate software APAS
®
 (Ariel Performance 
Analysis System, Ariel Dynamics, San Diego, USA). 2-D 
biomechanical analysis (sagittal plan) was carried out 
applying a two-segment model of the ankle joint, adopted 
from the model firstly developed by Varejão 
[40]
. The animals’ 
ankle angle was determined using the scalar product 
between a vector representing the foot and a vector 
representing the lower leg. With this model, positive and 
negative values of position of the ankle joint (º) indicate 
dorsiflexion and plantarflexion, respectively. For each step 
cycle the following time points were identified: Initial Contact 
(IC), Opposite Toe-off (OT), and Heel Rise (HR) and Toe-off 
(TO) 
[40-42]
 and were time normalized for 100% of step cycle. 
The normalized temporal parameters were averaged over all 
recorded trials. A total of 6 walking trials for each animal with 
stance phases lasting between 150 and 400 milliseconds 
were considered for analysis, since this corresponds to the 
animal’s normal walking velocity (20–60 cm/s) 
[40]
. 
 
2.7. Sciatic nerve stereology and histological analysis  
 
For the chronic phase study, histomorphometric analysis was 
performed.  Nerve samples  obtained from  the  10-mm-long  
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sciatic nerve segments distal to the neurotmesis site and 
from un-operated controls were processed for quantitative 
morphometry of myelinated nerve fibers 
[43]
. Fixation was 
carried out using 2.5% purified glutaraldehyde and 0.5% 
saccarose in 0.1M Sorensen phosphate buffer for 6-8 hours 
and resin embedding was obtained following Glauerts' 
procedure 
[44]
. Series of about 50 semi-thin transverse 
sections (2-µm thick) were cut using a Leica Ultracut UCT 
ultramicrotome (Leica Microsystems, Wetzlar, Germany) 
starting from the distal end of the specimen and stained by 
Toluidine blue. Stereology was carried out on one section, 
randomly selected from each of these series, using a 
DM4000B microscope equipped with a DFC320 digital 
camera and an IM50 image manager system (Leica 
Microsystems, Wetzlar, Germany). Systematic random 
sampling and D-dissector were adopted using a protocol 
previously described 
[45, 46]
. Fiber density and total number 
were estimated together with fiber and axon diameter and 
myelin thickness. For the acute phase study, the animals 
were euthanized 21 days after surgery and the samples’ 
histological preparation was as described for the 
histomorphometric analysis. For the hyper-acute phase study 
the nerve samples were collected at day 3, fixed in 10% 
buffered formalin, routinely processed, dehydrated and 
embedded in paraffin wax. Consecutive 4μm-sections were 
cut, stained with haematoxylin and eosin (HE) and submitted 
to histological evaluation where a quality analysis was 
performed by a single operator. 
 
2.8. Statistical analysis  
 
For data regarding the functional tests, means and standard 
deviations (SD) were computed and reported for each time 
point, including pre-operatively, and each experimental 
group. Differences between time points and between groups 
were tested by two-way analysis of variance (ANOVA) using 
a mixed model of within- (time of recovery) and between-
subjects (experimental groups) factors. In case ANOVA 
revealed an overall significant main effect of experimental 
group (between-subjects factor), pair-wise comparisons 
between the groups was undertaken using the post hoc 
Tukey’s HSD test. For stereology, statistical comparisons of 
quantitative data were subjected to one-way ANOVA test. All 
statistical procedures were performed by using the statistical 
package SPSS (version 17.0, SPSS, Inc) except 
stereological data that were analyzed using the software 
“Statistica per discipline bio-mediche” (McGraw-Hill, Milan, 
Italy). All data in this study are presented as mean ± SD. 
Statistical significance was accepted at p<0.05.  
 
3. Results 
 
3.1 UCX
®
 cells are Mesenchymal Stem Cells (MSCs) 
according to the ISCT  
 
MSCs, as defined by the International Society for Cellular 
Therapy (ISCT), are cells characterized by: a) their capacity 
to adhere to plastic; b) expression of specific surface 
markers, namely , CD73, CD90, and CD105, and no 
expression of  CD14, CD19, CD34, CD45 and HLA-DR. 
Additionally, according to the ISCT, MSCs are able to 
undergo tri-lineage differentiation into adipocytes, 
chondrocytes and osteoblasts 
[47]
. UCX
®
 cells were expanded 
to P5 where the culture appeared homogeneous and cells 
presented their typical fusiform, fibroblast-like, morphology 
(Figure 1A). As expected for MSC-type stem cells, flow 
cytometry analysis showed that over 95% of the cells in the 
population   were consistently  positive  for  the  cell  surface 
 
 
 
 
 
markers CD44, CD73, CD90 and CD105 and less than 2% 
positive for CD14, CD19, CD31, CD34, CD45 and HLA-DR 
(Figures 1B). In order to assay for UCX
®
 capacity for tri-
lineage differentiation, UCX
®
 expanded to P5 were incubated 
with specific differentiation media as described in the 
methods section. Results showed that UCX
®
 cells have the 
capacity for tri-lineage differentiation into adipocytes, 
chondrocytes and osteoblasts (Figures 1C i, ii, iii). Together 
these results show that UCX
®
 meet the minimum definition 
criteria of MSCs, according to the ISCT. 
 
3.2. Motor deficit and Nociception function  
 
For the acute study, at week 1 following sciatic nerve 
transection and end-to-end repair, every animal reached the 
12-sec end point of the WRL test, which is compatible with 
complete sensory loss in the plantar skin territory innervated 
by sciatic nerve. During the following weeks, withdrawal 
response latency improved, although at faster rate in the 
End-to-End group, compared with the End-to-EndUCX group 
(p=0.000; Figure 7A). Motor deficit in the immediate week 
following sciatic nerve transection and end-to-end repair 
reached values close to maximum (i.e., close to 1.0, 
compatible with complete absence of motor response in the 
affected hind-limb during the EPT test). Thereafter, the EPT 
response in the affected hind-limb somewhat improved until 
the end of week 3, particularly in the End-to-End group (End-
to-End group vs. End-to-EndUCX group, p=0.000; Figure 
7B).  
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Figure 7 – Mean Withdrawal Reflex Latency (WRL) and Extensor Postural 
Thrust (EPT) results for acute phase. Values in seconds (s) were obtained 
performing the Withdrawal Reflex Latency (WRL) test to evaluate the 
nociceptive function (A). Values of Motor Deficit were obtained performing 
Extensor Postural Thrust (EPT) test (B). Both tests were performed 
preoperatively (week 0), at day 7 (week 1), day 14 (week 2) and day 21 (week 
3).  The animals were sacrificed for morphological analysis at day 21 (week 3).  
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For the chronic study groups, data from WRL were analyzed 
through two-way Anova for repeated measures, comparing 
groups after sciatic neurotmesis treated with UCX
®
 (End-to-
EndUCX group), Floseal
®
 (End-to-EndFloseal group), these 
two treatments combined (End-to-EndFlosealUCX group) 
and an end-to-end control group (End-to-End). The results 
showed a significant interaction effect between time of 
recovery and treatment [F(33,220) = 3.097; p = 0.000]. This 
effect was explained by differences in recovery of the WRL 
after sciatic nerve neurotmesis between the end-to-end 
group (End-to-End) and the remaining experimental groups, 
with the former animals showing better recovery in this test. 
No differences in WRL recovery were found among animals 
treated with Floseal
®
 (End-to-EndFloseal group), MSCs 
(End-to-EndUCX group) or with combined Floseal
®
 plus 
UCX
®
 (End-to-EndFlosealUCX group) (Figure 8A). As a 
matter of fact, the Floseal
®
 did not improve the functional 
recovery when associated to the cellular system and when 
applied alone to the surgically reconstructed nerve, probably 
due to the gelatine matrix and the thrombin component, that 
works as glue, allowing for a tight contact between the two 
nerve stumps but not promoting the MSCs survival or growth 
factors and cytokines production in the injury site.  
 
The fact that the End-to-EndFloseal group and the End-to-
EndFlosealUCX group have reached normal values in terms 
of WRL, has demonstrated that our vehicle choice was 
successful.The potential added value of UCX
® 
in the chronic 
model was not noticeable by measuring WRL alone, although 
the End-to-EndUCX group also reached normal WRL values 
of at week 20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As for EPT, no differences in recovery were found among 
animals treated with Floseal
®
 (End-to-EndFloseal group), 
UCX
®
 (End-to-EndUCX group) or with combined Floseal
®
 
plus UCX
®
 (End-to-EndFlosealUCX group), with all treated 
groups presented elevated motor deficit at week 20, of 
0.82±0.07, 0.87±0.03, and 0.86±0.04, respectively (Figure 8A 
and 8B).These values were due to autotomy and 
contractures developed during the healing period although a 
deterrent substance was applied to animals’ right foot every 
48 hours 
[28, 29]
 (Figure 8B). 
 
3.3. Kinematics analysis 
 
Ankle joint kinematics during gait was assessed in the 
experimental treated groups at the end of the 20-weeks 
recovery time and was compared with data from uninjured 
control animals. Ankle angle was compared between groups 
at four selected instants belonging to the stance phase and 
significant differences between the groups were found for 
each of these time points, except for TO. Post hoc pair-wise 
comparisons showed that no differences in ankle joint angle 
existed between the uninjured control group and any of the 
sciatic-treated groups. However, differences in this 
parameter existed between experimental groups. At the 
instant of IC, the ankle joint angle was significantly different 
when comparing the End-to-End group to any of the 
remaining sciatic-treated groups (End-to-EndFlosealUCX, 
End-to-EndUCX and End-to-EndFloseal) (p<0.05). At OT, 
which occurs around 20% of the entire stance phase 
duration, differences between groups were now found 
between the End-to-End and End-to-EndUCX (p=0.023), and 
End-to-EndFlosealUCX (p=0.005), as well as between the 
two latter groups (p=0.015). Further differences in ankle 
angle at this time point were observed between the End-to-
End group and the group treated with UCX
®
 and Floseal
®
 
(End-to-EndFlosealUCX) (p=0.038). At the instant of HR, 
meaning the time during the stance phase of the rat’s gait 
cycle when the push off action begins, significant differences 
in ankle joint angle existed between End-to-EndFloseal 
animals and those within the End-to-EndFlosealUCX group 
(p=0.008) (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Mean Withdrawal Reflex Latency (WRL) and Extensor Postural Thrust 
(EPT) results for 20 weeks follow-up.  Values in seconds (s) were obtained 
performing Withdrawal Reflex Latency (WRL) test to evaluate the nociceptive 
function (A). Values of Motor Deficit were obtained performing Extensor Postural 
Thrust (EPT) test (B). This test has been performed pre-operatively (week 0), at 
week-1 and every 2 weeks after the surgical procedure until week 20, when the 
animals were sacrificed for morphological analysis.  
 
 
Figure 3 – Kinematic plots. Kinematic plots in the sagittal plane for the 
ankle angle (º) as it moves through the stance phase, obtained at week 20 
after the neurotmesis injury and surgical reconstruction of Control, End-to-
End, End-to-EndFlosealUCX, End-to-EndUCX, and End-to-EndFloseal 
groups. The mean of each experimental group is plotted (N = 6).  
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3.4. Histological and Stereological Analysis  
 
In the acute phase of the healing period (21 days) the 
samples revealed Wallerian degeneration in varying degrees, 
from mild to severe, in all material submitted for histology, 
hindering the observation of axonal regeneration (Figures 4A 
and 4B). A little retraction of the myelin membrane was 
observed, which could be caused by the nerve injury. 
However, the fiber organization was higher and the extent of 
fibrosis was lower in the End-to-EndUCX group (Figures 4A 
and 4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the hyper-acute phase (3 days), the histology of the End- 
to-End sample showed disruption of the perineurium, 
fascicles disorganization, proliferation of Schwann cells with 
axonal swelling and inflammatory infiltration in the 
endoneurium. Scarce neutrophils and multinucleated giant 
cells were also identified, mainly located around hair shafts, 
probably due to the surgical technique (Figure 5A). In turn, 
animals belonging to the End-to-EndFloseal and End-to-
EndFlosealUCX groups developed multiple foci of dystrophic 
calcification, often accompanied by a foreign body 
inflammatory reaction (Figures 5B and 5C).  
 
In the samples from the End-to-EndFlosealUCX group, this 
finding was even more prominent and extensive, associated 
with deposition of large amount of fibrin and hemorrhage 
which destroyed the normal architecture of the nerve (Figure 
5D).  Mild to moderate amount of mixed inflammatory 
infiltrate along with elongated mesenchymal cells 
circumscribing the perineurium were observed in the End-to-
EndUCX sample (Figure 5C). 
 
Such observations were indicative of an UCX
®
 - mediated 
induction of Wallerian degeneration necessary for proper 
nerve regeneration, an assumption that was confirmed by 
long-term observations (Figure 6) and stereological estimates 
(Table 1 and Figure 6F). While light microscopy analysis was 
restrictive, limiting our observations to the expected smaller 
size of regenerated nerve fibers relative to the controls, 
stereological analysis disclosed a significantly (p<0.05) larger 
axon diameter and thicker myelin thickness in the End-to-
EndFlosealUCX   group  when  compared   to  either  End-to-  
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Figure 4 – Histological images: acute phase. Histological analysis of the 
acute phase of the healing period (day 21 after neurotmesis). Figures A and 
B show cross sections of epon-embedded rat sciatic nerve from the same 
experimental group (End-to-EndUCX) with Toluidine Blue stain: Images of 
Wallerian degeneration - many axons with myelin degeneration 
(arrowheads) and some regenerating axon clusters (arrows). Original 
magnification: 400x. Scale bar = 10 µm. 
 
 
Figure 5 – Histological images: hyper-acute phase. Histological analysis of the 
hyper-acute phase of the healing period (day 3 after neurotmesis). Cross section of 
paraffin-embedded rat sciatic nerve, HE: (A) End-to-End: Destruction of 
perineurium and endoneurium and fascicles disorganization; (B) End-to-
EndFloseal: multiple foci of calcification (arrowheads) in the epineurium and fatty 
infiltration, associated with diffuse mononuclear inflammatory infiltrate (arrows); (C) 
End-to-EndUCX: mild to moderate amount of mixed inflammatory infiltrate (arrows) 
that circumscribe the perineurium; (D) End-to-EndFlosealUCX: multiple foci of 
calcification (arrowheads) associated with fibrin deposition and hemorrhage, with 
destruction of the perineurium and endoneurium. Original magnification: 100x. 
Scale bar = 50 µm. 
 
 
Figure 6 – Light micrographs images and histogram of the stereological 
parameters.Light micrographs of Toluidine blue-stained sciatic nerve semi-thin 
sections from four different experimental groups: Control (A) End-to-EndFlosealUCX 
(B) End-to-EndFloseal (C), End-to-EndCX  (D), End-to-End (E). Original 
magnification: 1000X. Scale bar = 5 µm.  Histogram summarizing results of 
stereological estimates of density, total number, diameter and myelin thickness in the 
4 experimental groups, Control, End-to-EndFlosealUCX, End-to-EndFloseal, End-to-
EndUCX, and End-to-End at week 20 after neurotmesis. Values are presented as 
mean ± SD (F). 
 
EndUCX or End-to-EndFloseal group (Table 1 and Figure 
6F). The results clearly demonstrate a synergistic positive 
effect on regenerated nerve fibers resulting from combined 
use of UCX
®
 with the Floseal
® 
vehicle.  
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Group 
Fiber Density (N 
/mm2) 
Fiber Number 
(N) 
Fiber diameter  
(µm) 
Axon diameter  
(µm) 
Myelin thickness 
(µm) 
Control 15,905±2,87 7,666±1,90 6,66±0,12 4,26±0,07 1,19±0,03 
End-to-End 20,612±1,607 14,624±1,642 4,06±0.30 3,31±0,09 0,58±0,03 
End-to-End FlosealUCX 26,009±6,512 12,255±2,290 4,57±0,51 2,88±0,42 0,85±0,05 
End-to-End Floseal 23,900±4,291 10,216±2,040 3,79±0,30 2,23±0,21 0,78±0,06 
End-to-End UCX 28,821±1,202 12,925±2,985 3,89±0,22 2,42±0,16 0,77±0,06 
 
Table 1 – Stereological quantitative paramaters. 
Stereological quantitative assessment of density, total number, diameter and myelin thickness of regenerated sciatic nerve fibers at week-20 after 
neurotmesis. Values are presented as mean ± SD 
 
Mesenchymal stem cells for nerve regeneration 
 
4. Discussion  
 
Nowadays, most tissue engineered nerve grafts are 
composed of a neural-scaffold prepared with a variety of 
biomaterials. The introduction of active cells, delivered by 
appropriate vehicles, could either replace or add to the 
system an important biochemical cue. The crucial role of 
MSCs in tissue renewal and regeneration has been well 
established 
[48]
. UCX
®
 cells in particular have already 
demonstrated to promote faster remission of local and 
systemic arthritic manifestations in a chronic adjuvant-
induced arthritis model 
[22]
. More recently, UCX
®
 grown in 
aggregates, that better mimic tissue environment, have 
produced a secretome richer in trophic factors, such as HGF, 
TGF-, G-CSF, VEGF-A, FGF-2, KGF and IL-6, that promote 
wound healing reactions, as demonstrated both in vitro by 
vasculogenesis, mitogenic and chemotactic assays, and in 
vivo, using a chemotaxis assay where UCX
® 
were shown to 
recruit surrounding bone marrow MSCs, known to be directly 
involved in tissue regeneration (results to be published 
elsewhere). 
 
In the present study the in vivo application of UCX
®
 was 
intended to improve the regeneration process in the rat 
sciatic nerve after a neurotmesis injury which was surgically 
reconstructed using end-to-end suture. In turn, Floseal
®
 is a 
biocompatible vehicle which can be easily used and it can be 
extruded from a syringe and applied topically to the bleeding 
area. This haemostatic agent has the ability to acquire 
irregular shapes fitting the wounded site. When the Floseal
®
 
is in contact with blood, the collagen particles are hydrated 
and swell, restricting the blood flow. The thrombin present 
converts the patient fibrinogen into a fibrin polymer, 
originating a clot around the lesion area of the nerve 
[49]
.  We 
hypothesize that such matrix could partially mimic the 
natural, physiological matrix of the umbilical cord (Wharton’s 
jelly) from which UCX
®
 cells are extracted, thus promoting 
three-dimensional (3D) cell-to-cell interactions. As seen by 
us, UCX
®
 cells grown in 3D spheroid-like structures are 
primed to a phenotype characterized by a secretome, which 
is richer in pro-healing factors so, most probably; Floseal
®
 
could indeed enhance beneficial 3D UCX
®
 cell-to-cell 
interactions. Furthermore, the introduction of Floseal
® 
in our 
chronic model formulation was intended to 1) promote end-
to-end nerve fiber contacts, and 2) reduce the flush away 
effect of the cells  after  administration,  thus  increasing  their 
permanance within the wounding site. The survival of 
transplanted MSCs in the injury site was previously reported 
by other published works. It was known at the starting point 
of our study that in other disease models characterized by 
inflammation sites, human MSCs (HMSCs) transiently home 
and niche to inflammatory sites, remaining viable in a xeno-
transplated rat for up to approximately 2 weeks in normal 
mice/rat, increasing their permanance in inflammation sites in 
diseased models, without detectable homing to other organs. 
Also, the bio-distribution of placental HMSCs, stably infected 
with a lentiviral construct expressing the luciferase gene, was 
performed in both immune-competent and immune-
compromised NOD/SCID and Balb/c mice. When 1 x 10
6
 
placental HMSCs were administrated, the bio-distribution 
pattern showed that the cells persisted only at the injection 
site (intramuscular for peripheral artery disease – PAD 
model, anterior paw) and did not distribute to other organs. 
Also, the placental HMSCs retained consistently high levels 
of luciferase expression, in vitro, for up to 3 weeks 
[50]
. 
Additionally, undifferentiated and differentiated HMSCs from 
the Wharton’s jelly were previously used by our research 
group in rat sciatic nerve reconstruction after axonotmesis 
and neurotmesis injuries. Undifferentiated HMSCs 
transplanted were negatively labelled to glial fibrillary acidic 
protein (GFAP), growth associated protein-43 (GAP-43), and 
neuronal nuclei (NeuN) 
[51]
 and presented positive effects on 
the functional and morphological recoveries of peripheral 
nerve after axonotmesis and neurotmesis. The HMSCs were 
applied either by local infiltration or associated in monolayer 
to several biomaterials namely poly(DL-lactide-ε-
caprolactone) (PLC) membranes. Other research groups 
have also proven the positive effects of the HMSCs in 
peripheral nerve regeneration, where the HMSCs were 
transplanted to the injury site and survived after the surgical 
procedure 
[52-55]
. The risk of immune rejection in our 
experimental setup was considered minimal since UCX
®
 cells 
have been xeno-implanted before into rabbits, rats and 
sheep without eliciting any compromising immune rejection 
[22, 56]
.  Due to the large importance of the Wallerian 
degeneration for subsequent cellular and molecular events 
that lead to nerve regeneration, it was important to evaluate 
the immediate Wallerian response and early nerve 
regeneration in the hyper-acute and acute phases, 
respectively.  When an axon is transected, the distal 
cytoskeleton disintegrates, its cell membrane disappears, 
and the axon fragments. 
 
Table 1 
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The Wallerian degeneration is accompanied by macrophages 
entering the transected area to remove myelin and axonal 
debris being first detected by light microscopy 36 to 44h after 
nerve transection in mice and rats, and reaching a peak 
around the third week. In the acute phase of the healing, our 
samples revealed Wallerian degeneration in varying degrees, 
from mild to severe, hindering the observation of axonal 
regeneration. On the other hand, nerve fiber organization 
was higher and the extent of fibrosis was lower when sciatic 
nerves were treated with UCX
®
, which suggests the 
importance of these cells in improving nerve regeneration 
when applied in the first days after neurotmesis, apparently 
by promoting a more efficient Wallerian degeneration. 
Theoretical repercussion of these histological observations 
performed during the hyper-acute and acute phases were 
confirmed by long-term observations and stereological 
estimates. While light microscopy limited the analysis to the 
observation of the expected smaller size of regenerated 
nerve fibers, stereological analysis was able to disclose a 
significantly larger axon diameter and higher myelin 
thickness in the End-to-EndFlosealUCX group, when 
compared to the End-to-EndUCX and End-to-EndFloseal 
experimental groups. These histological and 
histomorphometric analyses performed in the hyper-acute, 
acute and chronic phases also suggest that Floseal
®
 is an 
appropriate vehicle to deliver UCX
®
 to  peripheral nerve 
injuries. 
 
The myelin sheath was thicker in the regenerated nerves of 
UCX
®
-treated animals, suggesting that UCX
®
 might exert 
their positive effects on Schwann cells, the key element in 
Wallerian degeneration and consequent axonal regeneration. 
Previous results have demonstrated that the use of either 
undifferentiated or neuroglial-like differentiated Wharton jelly 
MSCs did enhance the recovery of sensory and motor 
function of the rat sciatic nerve in axonotmesis and 
neurotmesis injuries 
[11, 57]
. In turn, the degree of acute 
affection in thermal and nociceptive sensitive function as well 
as the rate of its recovery in the acute phase in the End-to-
End group was similar to the End-to-EndUCX.  Concerning 
EPT and WRL results in the chronic phase study, no 
differences in recovery were found between any of the 
treated groups. However, these tests are, to some extent, 
more dependent on the operator and therefore subject to 
human error. Potential pitfalls of the EPT do exist. It takes a 
certain training period for the tester to become comfortable 
handling the animals, and this comfort level is critical for the 
animal to behave in an unfrightened way. There is also a 
level of recognition of when the animal is bearing its 
maximum weight, which is critical since the tester is 
supporting the body of the animal at all times.  Also, it was 
observed autotomy and contractures in the treated animals, 
which limited the EPT test execution, although the application 
of a deterrent substance to the animals’ right paw every 2 
days. As a result, the use of different methods for an overall 
assessment of nerve function has long been recommended 
by several investigators 
[58]
.   In our lab we complement EPT 
and WRL techniques with a kinematics evaluation in order to 
reliably predict the potential therapeutic benefit of a nerve 
repair strategy. In this case, the kinematics analysis showed 
differences in ankle joint angle between experimental groups.  
At the instant of IC, the ankle joint angle determined for 
animals belonging to the End-to-End group was significantly 
different from any of  the  remaining  treated  groups.  At OT, 
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which occurs around 20% of the entire stance phase 
duration, differences were now found between the End-to-
End group and the groups treated with UCX
®
 (End-to-
EndUCX  group), and UCX
®
 administered with Floseal
®
 
(End-to-EndFlosealUCX), as well as between the two latter 
groups. At the instant of HR, meaning the time during the 
stance phase of the animal’s gait cycle, when the push off 
action begins, significant differences in ankle joint angle were 
measured between End-to-EndFloseal animals and End-to-
EndFlosealUCX animals. Despite ankle kinematics did not 
demonstrate clear differences between groups in terms of 
functional recovery; it is worthwhile noting that 20 weeks 
following sciatic nerve neurotmesis the ankle kinematics 
during the gait stance phase was similar to that of control 
animals. Because, it is unlikely that sciatic-injured animals 
can fully restore the normal ankle joint motion pattern during 
gait, we have to consider that our kinematics analysis might 
not have sufficient sensitivity to detect small differences in 
gait performance between experimental groups.  
 
5. Conclusions 
 
The histological analysis of the acute phase studies revealed 
that in the group treated with UCX
®
 alone the Wallerian 
degeneration was improved for the subsequent process of 
regeneration, the fiber organization was higher, and the 
extent of fibrosis was lower. The chronic phase experimental 
groups revealed that treatment with UCX
®
 induced an 
increased number of regenerated fibers and thickening of the 
myelin sheet.  
 
Kinematics analysis showed that the ankle joint angle 
determined for untreated animals was significantly different 
from any of the treated groups at the instant of IC. At OT and 
HR, differences were found between untreated animals and 
the groups treated with either UCX
®
 alone or UCX
®
 
administered with Floseal
®
. Overall, the UCX
®
 application 
presented positive effect in functional and morphologic 
recovery in both acute and chronic phases of the 
regeneration process. Kinematics analysis has revealed 
positive synergistic effects brought by Floseal
®
 as cell 
vehicle.  
 
Additionally, further studies will be necessary to clarify the 
potential of these cells in nerve and tissue regeneration. 
However, the results discussed herein show a promising 
effect of UCX
®
 in promoting myelin production in surgically 
reconstructed nerves after a neurotmesis injury. This effect 
was observed with human cells in rats and therefore, a more 
pronounced effect is expected in humans. A new gateway it, 
therefore, opened for using these cells in neurodegenerative 
diseases that are typified by demyelination. 
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BM-MSCs: bone marrow derived-mesenchymal stem cells 
CD:   cluster of differentiation 
EEPT:   experimental extensor postural thrust 
EPT:  extensor postural thrust 
FBS:   fetal bovine serum 
HR:   heel rise 
i.m.:   intra-muscular 
IC :  initial contact 
MHC:   major histocompatibility complex 
MSCs:   mesenchymal stem cells 
NEPT:   normal extensor postural thrust 
OT:   opposite toe-off 
SD:   standard desviation 
TGF-β1:  transforming growth factor – beta 1 
TO:   toe-off 
UC-MSCs: umbilical cord tissue-derived mesenchymal stem cells 
WRL:  withdrawal reflex latency 
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